Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

Supporting evidence

• Evaluation report

• Draft guidance consultation committee papers (PDF 5.86 MB)

  Published:

  11 December 2024

• Final draft guidance committee papers (PDF 4.9 MB)

  Published:

  11 December 2024